Monolithic Power price target raised to $80 from $65 at Pacific Crest Pacific Crest raised its price target on Monolithic as it believes that the company reported strong results and guidance. The firm is now more upbeat on the company's growth outlook and keeps an Outperform rating.
Biostar Pharmaceuticals approves 1-for-7 reverse stock split Biostar Pharmaceuticals announced that its Board of Directors unanimously approved a reverse split of its common stock at a ratio of 1-for-7, with anticipated trading on the post-split basis on NASDAQ commencing at the open of the stock market on February 5. In addition, the common stock will trade under a new CUSIP number. The reverse stock split will become effective upon the filing of the Company's Articles of Amendment to its Articles of Incorporation with the State of Maryland. The purpose of the reverse stock split is to raise the per share trading price of the Company's common stock to regain compliance with the minimum $1.00 continued listing requirement for the listing of its common stock on The NASDAQ Global Market.